Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H32N6O11 |
| Molecular Weight | 580.5445 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)C2=CC(=CC=C2OCC[C@H](NC1=O)C(=O)NCC(O)=O)[N+]([O-])=O
InChI
InChIKey=DVJXNXPFYJIACK-ULQDDVLXSA-N
InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1
| Molecular Formula | C24H32N6O11 |
| Molecular Weight | 580.5445 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Tavilermide (also known as MIM-D3) was developed as a tyrosine kinase TrkA receptor agonist for the treatment of patients with dry eye. The drug was studied in phase III clinical trial in treating the signs and symptoms of dry eye. In addition, was assumed that tavilermide could be studied for glaucoma.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Controlled Adverse Environment Chambers in Dry Eye Research. | 2018-04 |
|
| Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. | 2013 |
|
| An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. | 2011-10 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23836957
A total of 150 dry eye patients were randomized 1:1:1 to study medication (1% MIM-D3 (TAVILERMIDE), 5% MIM-D3, or placebo) and dosed twice daily (BID) for 28 days.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:31:30 GMT 2025
by
admin
on
Mon Mar 31 21:31:30 GMT 2025
|
| Record UNII |
NMG938VJ6T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10161
Created by
admin on Mon Mar 31 21:31:30 GMT 2025 , Edited by admin on Mon Mar 31 21:31:30 GMT 2025
|
PRIMARY | |||
|
9808372
Created by
admin on Mon Mar 31 21:31:30 GMT 2025 , Edited by admin on Mon Mar 31 21:31:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL3544981
Created by
admin on Mon Mar 31 21:31:30 GMT 2025 , Edited by admin on Mon Mar 31 21:31:30 GMT 2025
|
PRIMARY | |||
|
NMG938VJ6T
Created by
admin on Mon Mar 31 21:31:30 GMT 2025 , Edited by admin on Mon Mar 31 21:31:30 GMT 2025
|
PRIMARY | |||
|
263251-78-1
Created by
admin on Mon Mar 31 21:31:30 GMT 2025 , Edited by admin on Mon Mar 31 21:31:30 GMT 2025
|
PRIMARY | |||
|
DTXSID00180937
Created by
admin on Mon Mar 31 21:31:30 GMT 2025 , Edited by admin on Mon Mar 31 21:31:30 GMT 2025
|
PRIMARY | |||
|
BC-126
Created by
admin on Mon Mar 31 21:31:30 GMT 2025 , Edited by admin on Mon Mar 31 21:31:30 GMT 2025
|
PRIMARY | |||
|
Tavilermide
Created by
admin on Mon Mar 31 21:31:30 GMT 2025 , Edited by admin on Mon Mar 31 21:31:30 GMT 2025
|
PRIMARY | |||
|
C174759
Created by
admin on Mon Mar 31 21:31:30 GMT 2025 , Edited by admin on Mon Mar 31 21:31:30 GMT 2025
|
PRIMARY | |||
|
300000034366
Created by
admin on Mon Mar 31 21:31:30 GMT 2025 , Edited by admin on Mon Mar 31 21:31:30 GMT 2025
|
PRIMARY | |||
|
DB12441
Created by
admin on Mon Mar 31 21:31:30 GMT 2025 , Edited by admin on Mon Mar 31 21:31:30 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|